Question 1

What is CannEpil?

Accepted Answer

CannEpil is a Other.

Question 2

How often does CannEpil appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was CannEpil first tracked by Ergen?

Accepted Answer

First tracked on Jul 06, 2026.

Question 4

When was CannEpil last mentioned in news?

Accepted Answer

Last active on Jul 06, 2026.

Question 5

What is CannEpil's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is CannEpil in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving CannEpil?

Accepted Answer

Splash_Beverage_Group Licenses CannEpil Globally (Jul 06, 2026, 6 articles).

Question 8

How did the "Splash_Beverage_Group Licenses CannEpil Globally" event impact CannEpil?

Accepted Answer

CannEpil is a proprietary, cannabinoid-based investigational therapeutic for drug-resistant epilepsy, now exclusively licensed to Splash Beverage Group globally. It has established patient access and reimbursement in Europe and is pursuing U.S. FDA approval.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.